Alkermes plc buy melinda
Start price
19.06.17
/
50%
€57.15
Target price
05.07.17
€60.00
Performance (%)
5.28%
End price
05.07.17
€60.17
Summary
This prediction ended on 05.07.17 with a price of €60.17. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 24.471% | 24.471% | 97.623% | 61.812% |
| iShares Core DAX® | -1.358% | -2.165% | 2.078% | 52.680% |
| iShares Nasdaq 100 | -3.700% | -1.162% | 32.596% | 88.748% |
| iShares Nikkei 225® | -2.512% | 7.930% | 58.269% | 82.315% |
| iShares S&P 500 | -1.662% | -0.698% | 22.962% | 66.078% |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.